Impact of High-Dose Statin Therapy on Occurrence of In-stent Restenosis following Percutaneous Coronary Intervention: An Observational Study
DOI:
https://doi.org/10.70749/ijbr.v3i3.884Keywords:
High-Dose Statins, In-Stent Restenosis, PCI, Stent Thrombosis, DAPT AdherenceAbstract
Objective: To evaluate the impact of high-dose statin therapy on the occurrence of ISR following PCI and to assess whether high-dose statins reduce ISR and improve post-PCI outcomes. Methodology: A retrospective observational study was conducted at Hayatabad Medical Complex, Peshawar between June 2021 and June 2022. A total of 250 patients were included, with 125 patients receiving high-dose statins and 125 in the control group. Data on stent thrombosis, ISR, and DAPT adherence were collected, with statistical analysis conducted using the chi-square test. Results: The results showed that 65% of control patients experienced stent thrombosis compared to 42% in the high-dose statin group (p-value = 0.0032). Regarding DAPT adherence, 80% of control patients adhered well to the therapy, compared to 55% in the statin group. Despite the lower adherence in the statin group, the incidence of ISR was still significantly reduced. The chi-square test for stent thrombosis yielded a p-value of 0.0032, indicating a significant association between statin therapy and reduced ISR. Conclusion:High-dose statin therapy significantly reduces the occurrence of ISR post-PCI, highlighting its therapeutic benefits beyond lipid-lowering effects. Future research should focus on multi-center trials and optimal dosing strategies for long-term ISR prevention.
Downloads
References
Sinan U, Meriç BK, Bursa N, Moumin G, Kaya A, Ozkan AA. Evaluation of preprocedural statin loading on clinical outcomes in patients undergoing elective percutaneous coronary intervention. Front Cardiovasc Med. 2024;11. https://doi.org/10.3389/fcvm.2024.1435989
Khan AJ, Naz S. High Dose Statin as Upstream Therapy and the Frequency of Slow-Flow Phenomenon in Patients Undergoing Primary PCI or Immediate Invasive Therapy. J Heal Rehabil Res. 2024; https://doi.org/10.61919/jhrr.v4i1.741
Solangi AA, . N, Jamil A, Tahir M, . J, Ali K. Incidence and Outcome Predictors in the Treatment of In-Stent Restenosis with Drug-Eluting Ballons. Pakistan J Med Heal Sci. 2022; https://doi.org/10.53350/pjmhs221610929
Guo X, Shen R, Lu P, Lihong. Predictive values of novel high‑density lipoprotein‑related inflammatory indices in in‑stent restenosis among patients undergoing elective percutaneous coronary intervention. Exp Ther Med. 2023;27. https://doi.org/10.3892/etm.2023.12350
Yonezawa Y, Sakuma M, Abe S, Shibasaki I, Toyoda S, Inoue T. Repeated In-Stent Restenosis Despite Aggressive Lipid Loweringby PCSK-9 Inhibitor Treatment: A Case Report. Tohoku J Exp Med. 2021;255 2:123–6. https://doi.org/10.1620/tjem.255.123
Zhang J, Zhang Q, Zhao K, Bian Y, Liu Y, Xue Y. Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study. Medicine (Baltimore). 2022;101. https://doi.org/10.1097/md.0000000000031707
Khattak SN, Naqvi SWA, Ullah S, Shahid M, Ayaz M, . E. Frequency of in Stent Restenosis in Diabetic and Patients Undergoing PCI at Tertiary Care Cardiac Center. Pakistan J Med Heal Sci. 2022; https://doi.org/10.53350/pjmhs22169655
Abd-El-Aziz T, Mohamed R, Balata G, El-Azzazy O. GENES and In-Stent Restenosis: Review. Int J Res Pharm Sci. 2020;11:3993–8. https://doi.org/10.26452/ijrps.v11i3.2594
Li S, Luo C, Chen H. Risk factors of in-stent restenosis in patients with diabetes mellitus after percutaneous coronary intervention. Medicine (Baltimore). 2021;100. https://doi.org/10.1097/md.0000000000025484
Munteanu A, Chiriac L, Bolohan F, Niță D, Diaconescu C, Ioniţă I, et al. From Stenosis to Restenosis - The New Coronary Artery Disease Continuum in the PCI Era. Intern Med. 2020;17:61–8. https://doi.org/10.2478/inmed-2020-0125
Feng Q, Zhao Y, Wang H, Zhao J, Wang X, Shi J. A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients. Front Cardiovasc Med. 2022;9. https://doi.org/10.3389/fcvm.2022.857922
Limpijankit T, Chandavimol M, Srimahachota S, Siriyotha S, Thakkinstian A, Krittayaphong R, et al. No Paradoxical Effect of Smoking Status on Recurrent Cardiovascular Events in Patients Following Percutaneous Coronary Intervention: Thai PCI Registry. Front Cardiovasc Med. 2022;9. https://doi.org/10.3389/fcvm.2022.888593
Sajjad W, Nawaz T, Ali H, Amin M, Hussain S. Outcome of Primary Percutaneous Coronary Intervention for STEMI due to Stent Thrombosis. J Heal Rehabil Res. 2024 Feb 11;4(1):573–7. https://doi.org/10.61919/jhrr.v4i1.477
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
